Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3499-3506

  Van Cutsem, Eric ^a   Tabernero, Josep ^b   Lakomy, Radek ^c   Prenen, Hans ^a   Prausová, Jana ^d   Macarulla, Teresa ^b   Ruff, Paul ^e   Van Hazel, Guy A ^f   Moiseyenko, Vladimir ^h   Ferry, David ⁱ   McKendrick, Joe ^g   Polikoff, Jonathan ^j   Tellier, Alexia ^k   Castan, Rémi ^k   Allegra, Carmen ^l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

ⁱ RUSSELLS HALL HOSPITAL   (United Kingdom)

^j Oncology Research   (United States)

^k SANOFI   (France)

^l UNIVERSITY OF FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; APPETITE; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; EPISTAXIS; FEMALE; GASTROINTESTINAL PAIN; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; ULCER; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; YOUNG ADULT;

EID: 84867047384     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.8201     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
2. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004 (Pubitemid 41095110)
3. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
4. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
6. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
7. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398, 2002 (Pubitemid 34920936)
8. Kim ES, Serur A, Huang J, et al: Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 99:11399-11404, 2002 (Pubitemid 34920937)
9. Limentani S, Just R, Purdham A, et al: A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 26:167s, 2008 (suppl; abstr 3556)
10. Freyer G, Fumoleau P, You B, et al: A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 26:630s, 2008 (suppl; abstr 14539)
11. Patnaik A, Pipas M, Rosen LS, et al: A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 26:167s, 2008 (suppl; abstr 3558)
12. Isambert N, Freyer G, Zanetta S, et al: A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 26:167s, 2008 (suppl; abstr 3599)
13. Tew WP, Colombo N, Ray-Coquard I, et al: VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25:295s, 2007 (suppl; abstr 5508)
14. Rixe O, Verslype C, Khayat D, et al: A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs). J Clin Oncol 26:167s, 2008 (suppl; abstr 3557)
15. Verslype C, Spano C, Van Cutsem E, et al: Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in a phase I clinical trial of patients (pts) with advanced solid tumors (STs): Preliminary results. J Clin Oncol 26:631s, 2008 (suppl; abstr 14540)
16. Twardowski P, Stadler WM, Frankel P, et al: Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 76:923-926, 2010
17. Tew WP, Gordon M, Murren J, et al: Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 16:358-366, 2010
18. Lockhart AC, Rothenberg ML, Dupont J, et al: Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207-214, 2010
19. Leighl NB, Raez LE, Besse B, et al: A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 5:1054-1059, 2010
20. de Groot JF, Lamborn KR, Chang SM, et al: Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol 29:2689-2695, 2011
21. Tang P, Cohen SJ, Bjarnason GA, et al: Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial. J Clin Oncol 26:184s, 2008 (suppl; abstr 4027)
22. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006 (Pubitemid 46638957)
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
25. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49:407-424, 1998
26. Yao J, Wu X, Zhuang G, et al: Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A 108:11590-11595, 2011
27. Chu QS: Aflibercept (AVE0005): An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 9:263-271, 2009